CarlODonnell

Mega deals morph into mega problems for Wall Street

If 2015 was a dream year for Wall Street's top dealmakers, 2016 is starting to take a nightmarish turn.

New US inversion rules threatens $160b Pfizer-Allergan merger

The U.S. Treasury Department took new steps to curb tax-avoiding corporate "inversions," with the pending $160 billion merger of Pfizer Inc and Allerg

Roche plans to acquire gene-sequencing firm Pacific Biosciences